Involvement of matrix metalloproteinase-9 in amyloid-β 1-42-induced shedding of the pericyte proteoglycan NG2

Journal of Neuropathology and Experimental Neurology

Volumn 73, Issue 7, 2014, Pages 684-692

  Schultz, Nina ^a   Nielsen, Henrietta M ^b   Minthon, Lennart ^a   Wennström, Malin ^a  

^a LUND UNIVERSITY   (Sweden)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

Alzheimer disease; Amyloid; Matrix metalloproteinase 9; NG2 proteoglycan; Pericytes

Indexed keywords

2 [[(4 PHENOXYPHENYL)SULFONYL]METHYL]THIIRANE; ALPHA SMOOTH MUSCLE ACTIN; AMYLOID BETA PROTEIN[1-42]; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; LACTATE DEHYDROGENASE; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEOGLYCAN; PROTEOGLYCAN NG2; STROMELYSIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN PERICYTE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; RAT;

AMYLOID BETA-PEPTIDES; ANTIGENS; CELL AGGREGATION; CELL LINE; CELL SURVIVAL; CULTURE MEDIA; ENDOTHELIAL CELLS; HUMANS; L-LACTATE DEHYDROGENASE; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASE INHIBITORS; PEPTIDE FRAGMENTS; PERICYTES; PROTEOGLYCANS;

EID: 84903314983     PISSN: 00223069     EISSN: 15546578     Source Type: Journal    
DOI: 10.1097/NEN.0000000000000084     Document Type: Article

References (63)

1. Winkler EA, Bell RD, Zlokovic BV. Central nervous system pericytes in health and disease. Nat Neurosci 2011;14:1398-405
2. Armulik A, Genove G, Mae M, et al. Pericytes regulate the blood-brain barrier. Nature 2010;468:557-61
3. Bell RD, Winkler EA, Sagare AP, et al. Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging. Neuron 2010;68:409-27
4. Shimizu F, Sano Y, Maeda T, et al. Peripheral nerve pericytes originating from the blood-nerve barrier expresses tight junctional molecules and transporters as barrier-forming cells. J Cell Physiol 2008;217:388-99
5. Vagnucci AH Jr, Li WW. Alzheimer's disease and angiogenesis. Lancet 2003;361:605-8
6. Thomas WE. Brain macrophages: On the role of pericytes and perivascular cells. Brain Res Brain Res Rev 1999;31:42-57
7. Darland DC, Massingham LJ, Smith SR, et al. Pericyte production of cell-associated VEGF is differentiation-dependent and is associated with endothelial survival. Dev Biol 2003;264:275-88
8. Arihiro S, Ohtani H, Hiwatashi N, et al. Vascular smooth muscle cells and pericytes express MMP-1, MMP-9, TIMP-1 and type I procollagen in inflammatory bowel disease. Histopathology 2001;39:50-59
9. Takata F, Dohgu S, Matsumoto J, et al. Brain pericytes among cells constituting the blood-brain barrier are highly sensitive to tumor necrosis factor-alpha, releasing matrix metalloproteinase-9 and migrating in vitro. J Neuroinflamm 2011;8:106
10. Chen Q, Jin M, Yang F, et al. Matrix metalloproteinases: Inflammatory regulators of cell behaviors in vascular formation and remodeling. Mediators Inflamm 2013;2013:928315
11. Sagare AP, Bell RD, Zhao Z, et al. Pericyte loss influences Alzheimer-like neurodegeneration in mice. Nat Commun 2013;4:2932
12. Zlokovic BV. Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci 2005;28:202-8
13. Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci 2011;12:723-38
14. Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet 2006;368:387-403
15. Lee YJ, Han SB, Nam SY, et al. Inflammation and Alzheimer's disease. Arch Pharm Res 2010;33:1539-56
16. Brun A, Englund E. A white matter disorder in dementia of the Alzheimer type: A pathoanatomical study. Ann Neurol 1986;19:253-62
17. Englund E, Brun A.White matter changes in dementia of Alzheimer's type: The difference in vulnerability between cell compartments. Histopathology 1990;16:433-39
18. Farkas E, Luiten PG. Cerebral microvascular pathology in aging and Alzheimer's disease. Prog Neurobiol 2001;64:575-611
19. Kalaria RN. Vascular basis for brain degeneration: Faltering controls and risk factors for dementia. Nutr Rev 2010;68(Suppl 2):S74-87
20. Marchesi VT. Alzheimer's dementia begins as a disease of small blood vessels, damaged by oxidative-induced inflammation and dysregulated amyloidmetabolism: Implications for early detection and therapy. FASEB J 2011;25:5-13
21. Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat Rev Neurosci 2004;5:347-60
22. Sengillo JD, Winkler EA, Walker CT, et al. Deficiency in mural vascular cells coincides with blood-brain barrier disruption in Alzheimer's disease. Brain Pathol 2013;23:303-10
23. Verbeek MM, de Waal RM, Schipper JJ, et al. Rapid degeneration of cultured human brain pericytes by amyloid beta protein. J Neurochem 1997;68:1135-41
24. WilhelmusMM, Otte-Holler I, van Triel JJ, et al. Lipoprotein receptorYrelated protein-1 mediates amyloid-betaYmediated cell death of cerebrovascular cells. Am J Pathol 2007;171:1989-99
25. Ozerdem U, Grako KA, Dahlin-Huppe K, et al. NG2 proteoglycan is expressed exclusively by mural cells during vascular morphogenesis. Dev Dyn 2001;222:218-27
26. Stallcup WB, Huang FJ. A role for the NG2 proteoglycan in glioma progression. Cell Adhes Migr 2008;2:192-201
27. Ozerdem U, Stallcup WB. Pathological angiogenesis is reduced by targeting pericytes via the NG2 proteoglycan. Angiogenesis 2004;7:269-76
28. You WK, Yotsumoto F, Sakimura K, et al. NG2 proteoglycan promotes tumor vascularization via integrin-dependent effects on pericyte function. Angiogenesis 2013;7:61-76
29. Fukushi J, Makagiansar IT, Stallcup WB. NG2 proteoglycan promotes endothelial cell motility and angiogenesis via engagement of galectin-3 and alpha3beta1 integrin. Mol Biol Cell 2004;15:3580-90
30. Nielsen H, Ek D, Avdic U, et al. NG2 cells, a new trail for Alzheimer's disease mechanisms? Acta Neuropathol Commun 2013;1:7
31. Nielsen HM, Hall S, Surova Y, et al. Low levels of soluble NG2 in cerebrospinal fluid from patients with dementia with Lewy bodies. J Alzheimers Dis 2014; 40:343-50
32. Gibb WR, Luthert PJ, Janota I, et al. Cortical Lewy body dementia: Clinical features and classification. J Neurol Neurosurg Psychiatry 1989; 52:185-92
33. Nishiyama A. NG2 cells in the brain: A novel glial cell population. Hum Cell 2001;14:77-82
34. Asher RA, Morgenstern DA, Properzi F, et al. Two separate metalloproteinase activities are responsible for the shedding and processing of the NG2 proteoglycan in vitro. Mol Cell Neurosci 2005; 29:82-96
35. Liu H, Shubayev VI. Matrix metalloproteinase-9 controls proliferation of NG2+ progenitor cells immediately after spinal cord injury. Exp Neurol 2011;231:236-46
36. Larsen PH, Wells JE, Stallcup WB, et al. Matrix metalloproteinase-9 facilitates remyelination in part by processing the inhibitory NG2 proteoglycan. J Neurosci 2003;23:11127-35
37. Dreier R, Wallace S, Fuchs S, et al. Paracrine interactions of chondrocytes and macrophages in cartilage degradation: Articular chondrocytes provide factors that activate macrophage-derived pro-gelatinase B (pro-MMP-9). J Cell Sci 2001;114:3813-22
38. Ogata Y, Itoh Y, Nagase H. Steps involved in activation of the pro-matrix metalloproteinase 9 (progelatinase B)Ytissue inhibitor of metalloproteinases-1 complex by 4-aminophenylmercuric acetate and proteinases. J Biol Chem 1995;270:18506-11
39. Steenport M, Khan KM, Du B, et al. Matrix metalloproteinase (MMP)-1 and MMP-3 induce macrophage MMP-9: Evidence for the role of TNF-alpha and cyclooxygenase-2. J Immunol 2009;183:8119-27
40. Bouchard BA, Shatos MA, Tracy PB. Human brain pericytes differentially regulate expression of procoagulant enzyme complexes comprising the extrinsic pathway of blood coagulation. Arterioscler Thromb Vasc Biol 1997;17:1-9
41. Verbeek MM, Otte-Holler I,Wesseling P, et al. Induction of alpha-smooth muscle actin expression in cultured human brain pericytes by transforming growth factor-A1. Am J Pathol 1994;144:372-82
42. Tigges U,Welser-Alves JV, Boroujerdi A, et al. A novel and simple method for culturing pericytes from mouse brain. Microvasc Res 2012;84:74-80
43. Verbeek MM, Otte-Holler I,Wesseling P, et al. Induction of alpha-smooth muscle actin expression in cultured human brain pericytes by transforming growth factor-beta. Am J Pathol 1994;144:372-82
44. Korzeniewski C, Callewaert DM. An enzyme-release assay for natural cytotoxicity. J Immunol Methods 1983;64:313-20
45. Ramos-DeSimone N, Hahn-Dantona E, Sipley J, et al. Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. J Biol Chem 1999;274:13066-76
46. Horstmann S, Budig L, Gardner H, et al. Matrix metalloproteinases in peripheral blood and cerebrospinal fluid in patients with Alzheimer's disease. Int Psychogeriatr 2010;22:966-72
47. Klein WL. Synaptotoxic amyloid-beta oligomers: A molecular basis for the cause, diagnosis, and treatment of Alzheimer's disease? J Alzheimers Dis 2013;33(Suppl 1):S49-65
48. Stefani M. Structural features and cytotoxicity of amyloid oligomers: Implications in Alzheimer's disease and other diseases with amyloid deposits. Prog Neurobiol 2012;99:226-45
49. Biron KE, Dickstein DL, Gopaul R, et al. Amyloid triggers extensive cerebral angiogenesis causing blood brain barrier permeability and hypervascularity in Alzheimer's disease. PLoS One 2011;6:e23789
50. Ujiie M, Dickstein DL, Carlow DA, et al. Blood-brain barrier permeability precedes senile plaque formation in an Alzheimer disease model. Microcirculation 2003;10:463-70
51. Biron KE, Dickstein DL, Gopaul R, et al. Cessation of neoangiogenesis in Alzheimer's disease follows amyloid-beta immunization. Sci Rep 2013;3:1354
52. Dickstein DL, Biron KE, Ujiie M, et al. Abeta peptide immunization restores blood-brain barrier integrity in Alzheimer disease. FASEB J 2006;20:426-33
53. Pieper C, Pieloch P, Galla HJ. Pericytes support neutrophil transmigration via interleukin-8 across a porcine co-culture model of the blood-brain barrier. Brain Res 2013;1524:1-11
54. Yang Y, Estrada EY, Thompson JF, et al. Matrix metalloproteinaseYmediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat. J Cereb Blood Flow Metab 2007;27:697-709
55. Virgintino D, Errede M, Girolamo F, et al. NG2 modulates tight junction integrity in brain microvessels. Ital J Anat Embryol 2011:116
56. Farrall AJ, Wardlaw JM. Blood-brain barrier: Ageing and microvascular diseaseVsystematic review and meta-analysis. Neurobiol Aging 2009; 30:337-52
57. Wang H, Golob EJ, Su MY. Vascular volume and blood-brain barrier permeability measured by dynamic contrast enhanced MRI in hippocampus and cerebellum of patients with MCI and normal controls. J Magn Res Imaging 2006;24:695-700
58. Baloyannis SJ, Baloyannis IS. The vascular factor in Alzheimer's disease: A study in Golgi technique and electron microscopy. J Neurol Sci 2012;322:117-21
59. Buee L, Hof PR, Bouras C, et al. Pathological alterations of the cerebral microvasculature in Alzheimer's disease and related dementing disorders. Acta Neuropathol (Berl) 1994;87:469-80
60. Cordonnier C. Brain microbleeds. Pract Neurol 2010;10:94-100
61. Stallcup WB. The NG2 proteoglycan: Past insights and future prospects. J Neurocytol 2002;31:423-35
62. Stomrud E, Bjorkqvist M, Janciauskiene S, et al. Alterations of matrix metalloproteinases in the healthy elderly with increased risk of prodromal Alzheimer's disease. Alzheimers Res Ther 2010;2:20
63. Bell RD, Winkler EA, Singh I, et al. Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature 2012;485:512-16